Massachusetts-based Moderna said it plans to cut 10% of its global staff as part of its ongoing efforts to reduce annual ...

It’s not often that a CEO outright dismisses M&A prospects, but Moderna CEO Stéphane Bancel says the mRNA biotech has enough ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

CEO Stéphane Bancel on Friday stated that the company is lowering its annual revenue forecast due to the timing of shipments ...

"Moderna sharpens focus on $1.5bn cost cutting plan after 41% revenue slump" was originally created and published by ...

The Cambridge-based vaccine maker, which became a household name during the pandemic, is cutting its global workforce to ...

As of March 31, Moderna had $5.97 billion in cash and short-term investments, with total debt of $745 million. But the ...

Despite efforts to spare employees by scaling back R&D and reducing operating costs by roughly $1.5 billion over the next two ...

The number of biopharma professionals let go has increased year over year for three straight months. In July, nearly 8,000 ...

CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

The layoffs are part of an ongoing effort to reduce operating costs amid government and competitive challenges to its vaccine ...

In a memo to employees, Moderna CEO Stephane Bancel said the company expects to have fewer than 5,000 workers by the end of ...